ICCM
OtherIcecure Medical Ltd
$0.27-0.02 (-6.57%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ICCM Today?
No stock-specific AI insight has been generated for ICCM yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$22M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume645K
Avg Volume (10D)—
Shares Outstanding81.2M
ICCM News
20 articles- The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026Yahoo Finance·May 6, 2026
- IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. MarketYahoo Finance·May 5, 2026
- IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025Yahoo Finance·Apr 21, 2026
- IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private PlacementYahoo Finance·Mar 26, 2026
- IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free RatesBenzinga·Mar 25, 2026
- IceCure Appoints Meir Peleg as Chief Financial OfficerYahoo Finance·Mar 24, 2026
- Icecure Medical Ltd (ICCM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic U.S. ...Yahoo Finance·Mar 21, 2026
- IceCure Medical (ICCM) Q4 2025 Earnings TranscriptMotley Fool·Mar 17, 2026
- IceCure Medical Ltd Q4 2025 Earnings Call SummaryMoby·Mar 17, 2026
- IceCure Reports 2025 Full Year Financial & Operational ResultsYahoo Finance·Mar 17, 2026
- What To Expect From Icecure Medical Ltd (ICCM) Q4 2025 EarningsYahoo Finance·Mar 16, 2026
- U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast CancerYahoo Finance·Mar 11, 2026
- IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026Yahoo Finance·Mar 10, 2026
- American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast CancerYahoo Finance·Mar 9, 2026
- IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast FibroadenomasYahoo Finance·Mar 2, 2026
- Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the BoardYahoo Finance·Feb 27, 2026
- IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026Yahoo Finance·Feb 23, 2026
- IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer CryoablationYahoo Finance·Feb 19, 2026
- IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®Yahoo Finance·Feb 11, 2026
All 20 articles loaded
Price Data
Open$0.27
Previous Close$0.28
Day High$0.28
Day Low$0.26
52 Week High—
52 Week Low—
Fundamentals
Market Cap$22M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume645K
Avg Volume (10D)—
Shares Outstanding81.2M
About Icecure Medical Ltd
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SIC—
CIK—
Composite FIGI—
Share Class FIGI—